HK1164737A1 - Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir cobicistat - Google Patents

Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir cobicistat

Info

Publication number
HK1164737A1
HK1164737A1 HK12105696.2A HK12105696A HK1164737A1 HK 1164737 A1 HK1164737 A1 HK 1164737A1 HK 12105696 A HK12105696 A HK 12105696A HK 1164737 A1 HK1164737 A1 HK 1164737A1
Authority
HK
Hong Kong
Prior art keywords
cobicistat
elvitegravir
emtricitabine
tenofovir
bilayer tablets
Prior art date
Application number
HK12105696.2A
Other languages
English (en)
Chinese (zh)
Inventor
Reza Oliyai
Mark M Menning
Joanna M Koziara
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1164737(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HK1164737A1 publication Critical patent/HK1164737A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK12105696.2A 2009-02-06 2012-06-12 Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir cobicistat HK1164737A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15065209P 2009-02-06 2009-02-06
US15065509P 2009-02-06 2009-02-06
PCT/US2010/023226 WO2010091197A2 (en) 2009-02-06 2010-02-04 Tablets for combination therapy

Publications (1)

Publication Number Publication Date
HK1164737A1 true HK1164737A1 (en) 2012-09-28

Family

ID=41722740

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105696.2A HK1164737A1 (en) 2009-02-06 2012-06-12 Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir cobicistat

Country Status (31)

Country Link
US (2) US20100285122A1 (sl)
EP (1) EP2393485B1 (sl)
JP (2) JP5611242B2 (sl)
KR (2) KR101738325B1 (sl)
CN (1) CN102307573B (sl)
AP (1) AP3250A (sl)
AR (1) AR075369A1 (sl)
AU (1) AU2010210598B2 (sl)
BR (1) BRPI1008664A2 (sl)
CA (1) CA2750521A1 (sl)
CL (1) CL2011001885A1 (sl)
CY (1) CY1116852T1 (sl)
DK (1) DK2393485T3 (sl)
EA (2) EA021313B1 (sl)
EC (1) ECSP11011307A (sl)
ES (1) ES2548886T3 (sl)
HK (1) HK1164737A1 (sl)
HR (1) HRP20151009T1 (sl)
HU (1) HUE025822T2 (sl)
IL (1) IL214227A (sl)
MX (1) MX2011008289A (sl)
NZ (1) NZ594214A (sl)
PE (1) PE20110994A1 (sl)
PL (1) PL2393485T3 (sl)
PT (1) PT2393485E (sl)
SG (3) SG2014007744A (sl)
SI (1) SI2393485T1 (sl)
SM (1) SMT201500266B (sl)
TW (1) TWI444367B (sl)
UY (1) UY32424A (sl)
WO (1) WO2010091197A2 (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54237B9 (sr) 2006-07-07 2019-07-31 Gilead Sciences Inc Modulatori farmakokinetičkih svojstava terapeutika
AR065439A1 (es) * 2007-02-23 2009-06-10 Gilead Sciences Inc Derivados de tiazoles 1,3 no condensados,composiciones farmaceuticas que los contienen y usos como agentes antivirales, en particular anti hiv.
ES2553897T3 (es) 2008-05-02 2015-12-14 Gilead Sciences, Inc. El uso de partículas de vehículo sólido para mejorar la procesabilidad de un agente farmacéutico
UA114075C2 (xx) 2010-11-19 2017-04-25 БАГАТОШАРОВА ТАБЛЕТКА, ЩО МІСТИТЬ РИЛПІВІРИН HCl, ЕМТРИЦИТАБІН І ТЕНОФОВІРУ ДИЗОПРОКСИЛФУМАРАТ
ES2744926T3 (es) * 2010-11-29 2020-02-26 Formac Pharmaceuticals N V Formulaciones comprimidas de sílices mesoporosas ordenadas
BR112014000290B1 (pt) 2011-07-07 2022-05-10 Gilead Sciences, Inc. Forma de dosagem oral de combinação de darunavir, processo para preparação de uma forma de dosagem oral e uso de granulado de darunavir
CN103732594A (zh) 2011-08-16 2014-04-16 吉联亚科学公司 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐
CA2863662A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
AU2012327170A1 (en) * 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
CA2865491A1 (en) * 2012-03-01 2013-09-06 Gilead Sciences, Inc. Spray dried formulations
CN103830192A (zh) * 2012-11-27 2014-06-04 安徽贝克生物制药有限公司 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法
SG11201504857SA (en) 2012-12-21 2015-07-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
ES2945345T3 (es) 2015-06-30 2023-06-30 Gilead Sciences Inc Formulaciones farmacéuticas
PE20181207A1 (es) 2015-11-09 2018-07-23 Gilead Sciences Inc Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
ES2806604T3 (es) 2016-02-02 2021-02-18 Sandoz Ag Formas cristalinas de monofumarato de tenofovir alafenamida

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
DE10153078A1 (de) * 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
DE60329318D1 (de) * 2002-11-20 2009-10-29 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
RU2008128424A (ru) * 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
RS54237B9 (sr) * 2006-07-07 2019-07-31 Gilead Sciences Inc Modulatori farmakokinetičkih svojstava terapeutika
AR065439A1 (es) * 2007-02-23 2009-06-10 Gilead Sciences Inc Derivados de tiazoles 1,3 no condensados,composiciones farmaceuticas que los contienen y usos como agentes antivirales, en particular anti hiv.

Also Published As

Publication number Publication date
US20150150810A1 (en) 2015-06-04
SG2014007744A (en) 2014-05-29
HUE025822T2 (en) 2016-04-28
IL214227A (en) 2017-01-31
NZ594214A (en) 2013-05-31
EA201190125A1 (ru) 2012-01-30
SG10201706215UA (en) 2017-08-30
JP5911927B2 (ja) 2016-04-27
AU2010210598A1 (en) 2011-08-25
CA2750521A1 (en) 2010-08-12
JP2012517432A (ja) 2012-08-02
KR20110122729A (ko) 2011-11-10
UY32424A (es) 2010-09-30
HRP20151009T1 (hr) 2015-10-23
ES2548886T3 (es) 2015-10-21
WO2010091197A3 (en) 2011-06-03
AR075369A1 (es) 2011-03-30
MX2011008289A (es) 2011-09-15
SG173544A1 (en) 2011-09-29
PE20110994A1 (es) 2012-01-24
EA021313B1 (ru) 2015-05-29
PL2393485T3 (pl) 2015-12-31
KR20160093100A (ko) 2016-08-05
CL2011001885A1 (es) 2012-05-25
AU2010210598B2 (en) 2015-03-05
US20100285122A1 (en) 2010-11-11
KR101738325B1 (ko) 2017-05-19
SI2393485T1 (sl) 2015-10-30
AP3250A (en) 2015-05-31
SMT201500266B (it) 2016-01-08
IL214227A0 (en) 2011-09-27
KR101645759B1 (ko) 2016-08-04
TWI444367B (zh) 2014-07-11
CN102307573A (zh) 2012-01-04
JP5611242B2 (ja) 2014-10-22
EP2393485B1 (en) 2015-07-29
CY1116852T1 (el) 2017-04-05
EA201491658A1 (ru) 2015-05-29
DK2393485T3 (en) 2015-10-26
JP2014221845A (ja) 2014-11-27
CN102307573B (zh) 2013-09-11
EA030123B1 (ru) 2018-06-29
BRPI1008664A2 (pt) 2016-03-08
PT2393485E (pt) 2015-10-23
ECSP11011307A (es) 2011-10-31
TW201040142A (en) 2010-11-16
EP2393485A2 (en) 2011-12-14
WO2010091197A2 (en) 2010-08-12
AP2011005857A0 (en) 2011-10-31

Similar Documents

Publication Publication Date Title
HK1164737A1 (en) Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir cobicistat
HUS2000009I1 (hu) Kétrétegû tabletta készítmények
HRP20160807T1 (hr) Visoko koncentrirane farmaceutske formulacije koje sadrže protutijelo anti-cd20
SI2464342T1 (sl) Farmacevtske formulacije proti zlorabi zdravil
IL220509A (en) Compressed pyridinylpyrolidone, a pharmaceutical preparation and combination
HK1169960A1 (en) Pharmaceutical formulation
SI2655375T1 (sl) Derivati pirimidinona, njihova priprava in njihova farmacevtska uporaba
HK1161878A1 (en) Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof
IL214402A0 (en) Transdermal pharmaceutical preparations
ZA201104348B (en) Pharmaceutical preparation
ZA201200366B (en) 3-cyanoquinoline tablet formulations and uses thereof
GB0815972D0 (en) Pharmaceutical preparation
IL219617A0 (en) Pharmaceutical solid dosage form
PL2309983T3 (pl) Farmaceutyczna postać podawania zawierająca tetrahydrobiopterynę
EP2398475A4 (en) PHARMACEUTICAL PREPARATION AND DISPOSAL SYSTEM
IL229206A0 (en) Preparation and tablet containing raltagravir
GB0922537D0 (en) Pharmaceutical preparation
PL2651390T3 (pl) Orodyspersyjna tabletka farmaceutyczna na bazie zolpidemu
GB201115173D0 (en) Pharmaceutical preparation
GB201115179D0 (en) Pharmaceutical preparation
GB0906971D0 (en) Pharmaceutical preparation
GB0906003D0 (en) Oral drug formulation
HU1000106V0 (en) Dispenser for drugs in solid form
GB0914989D0 (en) Drug release formulations

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200202